NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Oasmia Pharmaceutical AB (NASDAQ:OASM) resulting from allegations that Oasmia may have issued materially misleading business information to the investing public.
On July 9, 2019, after the market closed, Oasmia reported that it terminated its “engagement and cooperation” with former executive chairman Julian Aleksov without any further renumeration, following a tax audit that revealed missing funds connected to suspicious transactions between Oasmia and companies controlled by Mr. Aleksov and his former father in-law. Oasmia also reported the matter to the Swedish Economic Crime Authority.
Following this news, shares of Oasmia fell $0.34 per share, or 13.08%, to close at $2.26 per share on July 10, 2019.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Oasmia investors. If you purchased shares of Oasmia please visit the firm’s website at http://www.rosenlegal.com/cases-register-1620.html to join the class action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.